Precision oncology in resected EGFR-mutant NSCLC
Mené en Chine sur 214 patients atteints d'un cancer du poumon non à petites cellules avec mutation EGFR (délétion de l'exon 19 ou substitution de l'exon 21) et ayant été réséqué (âge médian : 59 ans ; durée médiane de suivi : 27,5 mois), cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de l'aumolertinib en traitement adjuvant
The therapeutic landscape of early-stage EGFR-mutated non-small-cell lung cancer (NSCLC) has been irreversibly transformed by adjuvant EGFR tyrosine-kinase inhibitors.1 This paradigm shift began with the ADAURA trial, which established postoperative osimertinib as the first adjuvant targeted therapy to deliver durable survival benefit in molecularly defined NSCLC.2,3 Its effects extended beyond recurrence delay, providing clear evidence that early systemic intervention can improve cure rates and prevent metastatic relapse, especially in the brain. With the final overall survival results from ADAURA and the phase 3 ARTS trial of aumolertinib, reported by Liang Zhang and colleagues in The Lancet Oncology, adjuvant EGFR inhibition is evolving from proof of concept to global standard.
The Lancet Oncology , commentaire, 2026